pathophysiology of glucocorticoid-induced ONFH and device ways of preventing its occurrence.
Although clinic glucocorticoid use and ONFH occurrence are associated strongly, the exact mechanisms are still unclear although some factors such as coagulation abnormalities, hyperlipidaemia, oxidative stress and endothelial dysfunction are suggested to be involved. [5] [6] [7] [8] [9] These factors are thought to be associated with bone ischaemia due to the interruption of bone-vascular supply. Moreover, reports suggest that glucocorticoids can directly harm the endothelial cells, causing in vasoconstriction, thrombus formation in the femoral head and the disturbance of the coagulation-fibrinolysis system.
Collectively, these events decrease the blood supply to the trabecular bone and finally lead to ONFH. 10, 11 Therefore, maintaining the blood circulation within the femoral head is a key step to preventing glucocorticoid-induced ONFH.
Thus, it is possible that pro-angiogenesis substances can prevent ONFH by inhibiting endothelial cell injury. As a flavonoid isolated from Epimedii Herba, Icariin (ICA; C 33 H 40 O 15 ) is a major pharmacological active component of this plant. For thousands of years, ICA has been widely used in China, Japan and Korea as aphrodisiacs, tonics and anti-osteoporosis as recorded in the Chinese pharmacopeia. 12 From earlier reports, ICA has been found to be an effective treatment of bone metabolic-related diseases. Indeed, it enhances bone healing 13 and prevents osteoporosis 14 and ONFH. 15 Furthermore, it was reported vascular function can be promoted by ICA as well as inhibiting the endothelial cell dysfunction. 16 Chung et al 17 found that ICA could stimulate in vitro endothelial cell migration proliferation, tubulogenesis, and also promote angiogenesis in situ by activating PI3K/Akt signal pathway. The protective effect of ICA on vascular endothelial cells may be associated with its antiapoptosis effect. 16 However, to our knowledge, there is no study on whether ICA can prevent ONFH by improving the blood supply and promoting angiogenesis.
Given the pro-angiogenesis and other biological functions of ICA, we have been suggested that ICA might enhance the blood supply and promote angiogenesis in ONFH. In vitro and in vivo experiments were used to test this hypothesis.
| MATERIAL S AND ME THODS

| Cell culture and treatment
As reported in our previous study, the bone microvascular endothelial cells (BMECs) were acquired from patients undergoing hip arthroplasty as a result of femoral neck fractures. 18 Briefly, Dulbecco's modified Eagle's medium (DMEM; Gibco) was used to wash the aseptically collected cancellous bone (subchondral region) of the femoral head twice for 5 minutes. The supernatant was removed, and the bone debris warmly digested with 0.2% of type I collagenase (Sigma) for half an hour before they were separated with 0.25% Trypsin-EDTA (Gibco, Invitrogen) for 5 minutes. DMEM was then added to inactivate the enzyme solution. Filtration was conducted using a 70-μmol/L cell strainer, followed by centrifugation of the solution 430g for 6 minutes after which the supernatant was discarded. Cell culture was performed using endothelial cell medium (ECM; ScienCell) which contained 5 mL recombinant human vascular endothelial growth factor, 5% foetal bovine serum (FBS) and antibiotics at 37°C in 5% CO 2 . After every 3 days, the culture medium was changed. Upon reaching 80%-90% confluence, the cells were passaged. The BMECs from two to five passages were used in all experiments. The expression of the endothelial cell markers CD31 and vWF was examined by immunofluorescence. The Institutional Ethics Review Committee of the China-Japan Friendship Hospital approved this study. The approved guidelines and regulations were used in all experiments on BMECs, and informed consent was obtained from all study patients.
| Cell proliferation and viability
ICA (purity > 98%) was obtained from Solarbio. Dimethyl sulfoxide was used to dissolve it, and then, the solution was stored in the dark at −20°C. The effect of ICA and hydrocortisone (HC) on BMECs proliferation and viability was evaluated using the CCK-8 assay kit in accordance with the manufacturer's instructions. 100 μL of ECM and 10 μL of CCK-8 solution were added to each well after treatment in 96 wells, and an additional 2 hours of incubation was performed. The micro-plate reader at 450 nm was used to determine the absorbance value.
| BMECs migration assay
The effect of ICA and HC on BMECs migration was evaluated after performing transwell and wound-healing assays. For the woundhealing assay, 5 × 10 5 BMECs were cultured in 6-well plates up to 24 hours until they grew to the required confluence. Thereafter, they were treated with ICA or HC for 24 hours. Using a 200-μL pipette tip, a scratch was created on a cell monolayer. At 0 and 24 hours, the width of the scratch was measured, and the percentage of scratch recovery were determined. For the transwell assay (Corning, 8 μm), 
| BMECs tube formation assay
After coating with 100 μL of Matrigel (BD, USA), the 96-well plate kept under 37°C for 1 hour to allow it to solidify and polymerize.
BMECs were pre-treated with ICA or HC for 24 hours with FBS-free condition ECM. Thereafter, seeding of a total of 2 × 10 5 cells/well was performed on the Matrigel. Tube formation process was monitored by microscopic visualization at the end of a 6-hour incubation and later quantified by NIH ImageJ.
| Immunofluorescence staining
BMECs were embedded on round coverslips before placing them in a 12-well plate. Paraformaldehyde (4%) was used to fix the BMECs for 20 minutes after reaching the desired confluence. Then, 0.1% Triton X-100 was used to treat them for 15 minutes, and blocking was done for 30 minutes at 37°C using 10% FBS. Subsequently, using rabbit antibodies against CD31 (Abcam, 1:200) and vWF (Abcam, 1:200), the slips were labelled at 4°C overnight. On the following day, PBS was used to wash the slices three times and Alexa Fluor™488 secondary antibodies (Invitrogen) were employed to immerse them for 1 hours at 37°C. Then, 5μg/mL 4',6-diamidino-2-phenylindole (DAPI) was used to stain the slips for 30 seconds, rinsing done by PBS after which a confocal laser scanning microscope was used to analyse the results.
| Western blot analysis
After treatment of BMECs for 24 hours, proteins were extracted by RIPA lysis buffer and BCA assay kit (Beyotime) was applied for the measurement of total protein concentration. Thereafter, heating at 95°C for 5 minutes resulted in the denaturing of the proteins. SDS-PAGE was used to separate 30 μg sample of proteins, and then, they were transferred to PVDF membranes. Blocking of the membranes with 5% dried skimmed milk was done and then incubated by primary antibodies against VEGF(Abcam, 1:1000), Akt (Abcam, 1:1000), p-Akt (Abcam, 1:500), Bax (Abcam, 1:1000), Bcl-2 (Abcam, 1:500) and β-actin (Abcam, 1:3000) overnight at 4°C followed. Afterwards, incubation with their corresponding secondary antibodies was conducted. The bands were observed with Electrochemiluminescence Plus Reagent (Invitrogen). Image Lab 3.0 software was used to quantify the band intensity.
| The qRT-PCR assay
TRIzol reagent (Invitrogen) assisted in obtaining the total RNA extracts, and cDNA (Takara, Japan) was used to synthesize by the 1ug of total RNA. The SYBR Green system (Bio-Rad) was used to perform qPCR. At a temperature of 95°C for 3 minutes, amplification of cDNA samples included 40 cycles of 95°C for 15 seconds and 60°C for 45 seconds. Table 1 shows the forward and reverse primers.
Target gene expressions were normalized to the housekeeping gene β-actin and calculated by the 2 −△△Ct method.
| In vivo studies
| Animal grouping and treatment
The Animal Research Committee of the China-Japan Friendship Hospital approved all procedures that were carried out. Thirty SD rats, weighing 260 ± 20 g, were randomly assigned into the following groups: (a) the control, (b) the methylprednisolone (MP) group and (c) the MP + ICA group. Sequential drug administration for rats in the MP group and the MP + ICA group was performed to develop the ONFH model. The experimental rats were administered 10 μg/ kg of lipopolysaccharide every 24 hours for 2 days. Then, the rats were intramuscularly injected with a dosage of 40 mg/kg MP (Pfizer Pharmaceutical, China) three times every 24 hours for 3 days as previously described. 19 For the control group, a sham injection with normal saline administered was given to each rat. Gavage feeding of rats in the MP + ICA group with a daily dose of 60 mg/kg ICA for 6 weeks after the last injection of MP was carried out. The similar dosage of saline as the MP + ICA group was administered for rats from the control group and the MP group. At 6 weeks from the final injection of MP, all rats were killed. Femoral heads were collected for further assessment. In all groups, there was no rat dead before the assessment. 20 Then, the bilateral femoral heads were isolated following an overnight storage of rats at 4°C.
| Angiography and micro-CT scanning
After decalcification, micro-CT scanning at a voxel of 9 microns was used to examine the samples and quantify the total vessel volume with CTVol software.
| Haematoxylin and eosin staining
Paraformaldehyde was used to fix the femoral head samples for 24 hours at 4°C and then decalcified with 10% Subsequently, calculation and counting of the mean density (IOD/ area) were done.
| Statistical analysis
All data are presented as the mean ± standard deviation (SD). A one-way analysis of variance was used to compare the experimental groups followed by Tukey's post hoc test, and then, the count data was performed by Fisher's exact probability test. The SPSS version 21.0 (SPSS Inc) was used for statistical analysis. Values with P < .05
were regarded as statistically significant.
| RE SULTS
| Culture and identification of BMECs
BMECs were isolated from femoral bone tissue at the subchondral region. Some cell clusters and scattered individual spindleshaped cells were noted 48 hours after the initial cell culture ( Figure 1A,B ). After 14 days of culture, the cells developed the typical cobblestone morphology of endothelial cells. The tube formation assay results confirmed the angiogenic property of the cells in vitro ( Figure 1C ). The isolated cells showed a high expression of CD31 and vWF ( Figure 1D ,E). These results indicated that these cells were BMECs and thus were used in the experiments described below.
| Effects of HC and ICA on BMECs proliferation
The proliferative capacity of BMECs for 48 hours by the CCK8 assay was examined by the impact of HC (0-0.2 mg/mL) or ICA (10 −7 -10 −3 mol/L) on it (Figure 2A,B ). HC at 0.1 mg/mL obviously suppressed cell proliferation, which is consistent with our previous studies. 21 
| Effects of HC and ICA on BMECs migration and angiogenesis
We performed in vitro tests for migration, wound healing and tube formation to determine whether ICA affects migration and angiogenesis of BMECs in the presence of HC. HC inhibited the wound recovery and migration of BMECs (both P < .01) as confirmed by the results of wound-healing and migration assay, while ICA rescued the wound recovery process and migration of BMECs (P < .05 and P < .01, respectively). It was also found that BMECs treated with ICA alone showed higher migration and wound recovery compared to the control group ( Figure 3A -C,E,F).
In the tube formation assay, a smaller tube length and no loop formation were seen in the HC group. But more visible and longer tubes were observed in the HC + ICA group. Besides, we observed that BMECs treated with ICA alone had better angiogenesis activity compared to the control group ( Figure 3D ,G,H). 
| ICA promoted angiogenesis-related cytokine expression as well as the activation of Akt in the BMECs
| ICA suppressed the Bax and Bcl-2-mediated apoptosis in the BMECs
The expression of Bcl-2 and Bax in the BMECs was detected using Furthermore, the protein levels of Bcl-2 and Bax in the ICA group were comparable to those of the control group.
| Histological analysis
The definition of ONFH is the diffuse presence of empty lacunae or pyknotic nuclei of osteocytes in the bone trabeculae accompanied by surrounding bone marrow cell necrosis as previously reported. 22 According to histological analysis, 2 of the 10 rats from the ICA group and 8 of the 10 rats from the MP group developed ONFH. Fisher's exact probability test showed an obvious decrease in the incidence of ONFH in the ICA groups (P < .05; Figure 6E -F). No ONFH was detected in the control group (Figure 6A,B ). Relative to the MP + ICA group, more empty lacunae and necrotic bone marrow cells were noted in the MP group (Figure 6C,D) . The rate of empty lacunae of the ICA groups was significantly lower relative to the MP group (P < .1; Figure 6G ).
| ICA protected the blood vessels from the glucocorticoid-induced ONFH in rats
To assess the blood supply of the femoral head, we applied angiography to visualize angiogenesis in vivo. Angiographic results showed that MP markedly destroyed the blood vessels of femoral heads. However, co-administration of ICA produced significant protective effects on blood vessels of the femoral heads ( Figure 7A) .
Quantitatively, the MP group had significantly lower volume percentages and blood vessel volumes relative to the control and ICA groups ( Figure 7C ). In addition, immunohistochemical staining for CD31, a marker of endothelial cells, revealed similar results as angiography. MP significantly decreased CD31 expression, an effect that was reversed by ICA ( Figure 7B,D) . Therefore, ICA promotes angiogenesis in rats with ONFH.
| D ISCUSS I ON
In this study, the negative effects of HC on BMECs viability, tube formation, apoptosis, angiogenesis-related cytokines expression and F I G U R E 3 Effect of HC and ICA on BMECs migration and angiogenesis. A, B, E, Wound-healing results of BMECs for different treatments. BMECs were treated with 10 −5 mol/L ICA, 0.1 mg/mL HC and combination of 10 −5 mol/L ICA and 0.1 mg/mL HC for 24 h. *indicated P < .05; **indicated P < .01. C, F, Transwell assay results of BMECs for different treatments. BMECs were treated with 10 −5 mol/L ICA, 0.1 mg/mL HC and combination of 10 −5 mol/L ICA and 0.1 mg/mL HC in the lower chamber for 12 h incubation. *indicated P < .05; **indicated P < .01. D, G, H, Tube formation assay results of BMECs for different treatments. BMECs were treated with 10 −5 mol/L ICA, 0.1 mg/mL HC and combination of 10 −5 mol/L ICA and 0.1 mg/mL HC for 6 h of incubation on the Matrigel.*indicated P < .05; **indicated P < .01 the activation of Akt through in vitro experiments were found to be reduced by ICA. We also showed that ICA administration produced significant improvement in blood vessel functions in the femoral head of glucocorticoid-treated rats.
As studies have shown that endothelial cell injury and dysfunction are closely associated with the pathogenesis of ONFH, many studies have used human umbilical vein endothelial cells (HUVECs)
to replicate the ONFH endothelial condition in vitro. Kerachian et al 23 suggested that in addition to the heterogeneity of endothelial cells in the whole body, the endothelial dysfunction occurs at the microvascular bed in the ONFH. However, HUVECs are derived from a macrovascular bed that does not exist in adults. Therefore, in our study, we used BMECs obtained from the subchondral bone of the femoral head to enable a more specific molecular study instead of using the non-specific HUVECs. We observed that the isolated cells formed adherent colonies and exhibited a typical cobblestone-like morphology of endothelial cells after 14 days of culture. As previously demonstrated, endothelial cells in vitro will form capillary-like tubules when exposed to extracellular matrix protein. 24 Similarly, we found that BMECs formed a capillary tubular pattern when incubated on the Matrigel for 6 hours, which contains a mixture of extracellular matrix proteins. Besides, CD 31 25 and vWF, 26 the standard markers of endothelial cells, were highly expressed as revealed by the immunofluorescence staining. All these confirmed the presence of endothelial cells in the isolates of the subchondral bone of the femoral head.
Glucocorticoid is a widely used drug in the clinics and has been the leading cause of non-traumatic ONFH. Seguin et al 27 reported that ONFH and regional endothelial dysfunction are strongly associated. Glucocorticoids can directly injure endothelial cells, 10 decrease blood flow to the femoral head 28 and compromise microcirculation. 29 Eventually, this leads to ischaemia and hypoxia which cause avascular necrosis of the femoral head and impairs the bone function and structure. 30 Consistent with previous findings, our in vitro results showed that glucocorticoid inhibited angiogenesis of BMECs, including migration, wound healing and tube formation. 31 Furthermore, we found that ICA had a protective role against the negative effects of glucocorticoid on BMECs, which demonstrates that ICA has the potential to promote angiogenesis. VEGF has been shown to be an important cytokine in angiogenesis. It can act directly on endothelial cells to promote proliferation, migration and vascularization. 32, 33 Hence, dysregulation of VEGF will have an effect on angiogenesis and consequently the repair process. 9 In this study, we observed that HC significantly decreased VEGF expression in BMECs while ICA promoted its expression.
Subsequently, we studied the expression of other factors related to angiogenesis. CD31 is mainly expressed in endothelial cells and is an endothelial marker. 25 Endothelial cells specifically produce vWF, a marker that stains newly formed vessels. 26 Stimulation of maturation of the vessel wall is as a result of PDGF-B, which is secreted by endothelial cells. 34 Compared to the HC group, our study showed that the mRNA expression level of CD31, vWF and PDGF-B was substantially higher in the HC + ICA group. Moreover, ICA alone also increased the expression of these factors, which further supports the findings that ICA promotes angiogenesis.
The PI3K/Akt pathway has been found to regulate a wide range of fundamental cell functions such as survival, growth, migration, proliferation and cell cycle progression. 35, 36 It has been shown that activation of the survival signal PI3K/Akt pathway is closely associated with vascular angiogenesis. 37 Previous study showed that ICA stimulated angiogenesis in HUVECs by activation of Akt. 17 Our results showed that HC decreased Akt activation and angiogenesis in BMECs, while ICA increased Akt activation and angiogenesis. These results suggest that the angiogenic activity of ICA requires the PI3K/ Akt signal pathway.
Apoptosis is a normal physiological process that plays an essential role in the progression of ONFH. 38 The endothelium is a crucial site where the control of apoptosis during angiogenesis occurs. 39 Furthermore, the suppression of endothelial cell apoptosis is necessary for the maintenance of blood vessel integrity and for angiogenesis. 40 Previous studies have shown that increased expression of Bcl-2 prevents apoptosis while increased expression of Bax promotes apoptosis. 41, 42 Therefore, the balance between the In the in vivo study, we used LPS combined MPS techniques to develop a rat model of ONFH as these methods have been proved to be effective in modelling ONFH. 44 The MP group showed histopathological characteristics such as empty lacunae and bone marrow cell necrosis. After the ICA treatment, the rate of empty lacunae decreased obviously. The results demonstrated that ICA can prevent glucocorticoid-induced ONFH. In addition, we performed the micro-CT-based microangiography to visualize and quantify the blood circulation in the rat femoral head. We found that there were significantly more blood vessels in the ICA and control groups compared with the MP group. Furthermore, using immunohistochemical techniques, we observed that the expression of CD31, a biomarker for angiogenesis, was enhanced in the ICA group relative to the MP group, which further affirmed our hypothesis.
Our study had some limitations. First, many signal pathways regulate angiogenic activity; however, our present study only investigated the PI3K/Akt signal pathway. Further studies should investigate them. Second, the dose-timing effects of ICA treatment on rats were not assessed. In the present study, only one dose was applied, which was based on data from preliminary studies. 45 Whether longer treatment periods would more effective was also not conducted in this study. Further studies are needed to elucidate that.
In conclusion, this study revealed that ICA promotes angiogenesis of BMECs in vitro and improves femoral head blood vessel volume of rats treated with glucocorticoid. Therefore, it may be an effective and novel therapeutic agent for preventing glucocorticoidrelated ONFH.
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